# US 2001/0018055 A1 · Deletion mutants of virulence factors of pasteurellaceae

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0018055 A1
- Document ID: US20010018055A1
- Status: Published application
- Kind: A1
- Application number: 09/736,169
- Filed: 2000-12-15
- Published: 2001-08-30
- Earliest claimed: 1997-09-25
- Inventors: Robert E. Briggs; Fred M. Tatum
- Web page: https://patentgrep.com/patent/US20010018055A1

## CPC

- C12N 1/205: Bacterial isolates
- A61K 39/102: {Pasteurellales, e.g. Actinobacillus}, Pasteurella; Haemophilus
- C07K 14/285: from Pasteurellaceae (F), e.g. Haemophilus influenza
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Virulence factor mutants of Pasteurellaceae provide excellent safety and efficacy when used as vaccines in mammals, especially ruminants, for example cattle, sheep, and goats, subject to pneumonic pasteurellosis. They can be administered by a variety of routes. Especially preferred is the use in animal feeds. The mutants are not reverting and contain no foreign DNA and no introduced antibiotic resistance genes.

## Claims

### Claim 1

An isolated and purified bacterium of the family Pasteurellaceae comprising a mutant virulence factor, wherein said bacterium:
a) expresses no biologically active form of the virulence factor;
b) expresses an in-frame deletion form of the virulence factor which induces antibodies which specifically bind to virulence factor; and
c) contains no foreign DNA.

### Claim 2 (depends on 1)

The bacterium of the family Pasteurellaceae of claim 1 wherein the virulence factor is an RTX toxin.

### Claim 3 (depends on 1)

The bacterium of the family Pasteurellaceae of claim 1 wherein the virulence factor is neuraminidase.

### Claim 4 (depends on 3)

The bacterium of the family Pasteurellaceae of claim 3 which is a Pasteurella multocida.

### Claim 5 (depends on 1)

The bacterium of the family Pasteurellaceae of claim 1 wherein the virulence factor is glycoprotease.

### Claim 6 (depends on 5)

The bacterium of the family Pasteurellaceae of claim 5 which is a Pasteurella multocida.

### Claim 7 (depends on 1)

The bacterium of the family Pasteurellaceae of claim 1 wherein the virulence factor is hemolysin.

### Claim 8 (depends on 7)

The bacterium of the family Pasteurellaceae of claim 7 which is a Haemophilus somnus.

### Claim 9 (depends on 1)

The bacterium of the family Pasteurellaceae of claim 1 wherein the virulence factor is serum-resistance.

### Claim 10 (depends on 9)

The bacterium of the family Pasteurellaceae of claim 9 which is a Haemophilus somnus.

### Claim 11 (depends on 1)

The bacterium of the family Pasteurellaceae of claim 1 wherein the virulence factor is dermonecrotic toxin.

### Claim 12 (depends on 11)

The bacterium of the family Pasteurellaceae of claim 11 which is a Bordetella bronchiseptica.

### Claim 13 (depends on 2)

The bacterium of the family Pasteurellaceae of claim 2 wherein the virulence factor is cytotoxic distending toxin.

### Claim 14 (depends on 2)

The bacterium of the family Pasteurellaceae of claim 2 wherein the virulence factor is adenylate cyclase.

### Claim 15 (depends on 14)

The bacterium of the family Pasteurellaceae of claim 14 which is a Bordetella bronchiseptica.

### Claim 16 (depends on 1)

The bacterium of the family Pasteurellaceae of claim 1 wherein the virulence factor is filamentous hemagglutinin.

### Claim 17 (depends on 16)

The bacterium of the family Pasteurellaceae of claim 16 which is a Bordetella bronchiseptica.

### Claim 18 (depends on 1)

The bacterium of the family Pasteurellaceae of claim 1 wherein the virulence factor operon comprises no antibiotic resistance genes.

### Claim 19 (depends on 1)

The bacterium of the family Pasteurellaceae of claim 1 wherein the virulence factor is capsule biosynthesis.

### Claim 20 (depends on 19)

The bacterium of the family Pasteurellaceae of claim 19 which is a Pasteurella multocida.

### Claim 21 (depends on 1)

The bacterium of the family Pasteurellaceae of claim 1 wherein the bacterium comprises a mutation which is non-reverting, said mutation resulting in the inability of the bacterium to express biologically active virulence factor.

### Claim 22 (depends on 1)

A method of inducing immunity to pneumonic pasteurellosis in a mammal, comprising the step of:
administering the bacterium of claim 1 to a mammal whereby immunity is induced.

### Claim 23 (depends on 22)

The method of claim 22 wherein the step of administering is via the oral route.

### Claim 24 (depends on 23)

The method of claim 23 wherein the bacterium is top-dressed on the feed of the ruminant.

### Claim 25 (depends on 22)

The method of claim 22 wherein the step of administering comprises injecting the bacterium subcutaneously.

### Claim 26 (depends on 22)

The method of claim 22 wherein the step of administering comprises injecting the bacterium intradermally.

### Claim 27 (depends on 22)

The method of claim 22 wherein the step of administering comprises injecting the bacterium intramuscularly.

### Claim 28 (depends on 22)

The method of claim 22 wherein the step of administering is via the nose.

### Claim 29 (depends on 22)

The method of claim 22 wherein the mammal is a ruminant.

### Claim 30 (depends on 1)

A feed for ruminants which comprises the bacterium of claim 1.

### Claim 31

A vaccine for reducing morbidity in a mammal, comprising:
a bacterium of the family Pasteurellaceae comprising a mutant virulence factor,
wherein the bacterium:
a) expresses no biologically active form of the virulence factor,
b) expresses a form of the virulence factor which induces antibodies which specifically bind to the virulence factor; and
c) contains no foreign DNA; and
a pharmaceutically or veterinarily acceptable carrier.

### Claim 32

An isolated Pasteurellaceae virulence factor molecule which:
a) contains an in-frame deletion:
b) is biologically inactive;
c) induces antibodies which specifically bind to virulence factor; and
d) contains no foreign amino acid sequences.

### Claim 33 (depends on 22)

A method of inducing immunity to pneumonic pasteurellosis in a mammal, comprising the step of:
administering the virulence factor protein of claim 22 to a mammal whereby immunity is induced.

### Claim 34 (depends on 33)

The method of claim 33 wherein the step of administering is via the oral route.

### Claim 35 (depends on 34)

The method of claim 34 wherein the virulence factor protein is top-dressed on the feed of the mammal.

### Claim 36 (depends on 33)

The method of claim 33 wherein the step of administering comprises injecting the virulence factor protein subcutaneously.

### Claim 37 (depends on 33)

The method of claim 33 wherein the step of administering comprises injecting the virulence factor protein intradermally.

### Claim 38 (depends on 33)

The method of claim 33 wherein the step of administering comprises injecting the virulence factor protein intramuscularly.

### Claim 39 (depends on 33)

The method of claim 33 wherein the step of administering is via the nose.

### Claim 40 (depends on 32)

A feed for ruminants which comprises the virulence factor protein of claim 32.

### Claim 41

Avaccine for reducing morbidity in a mammal, comprising: a Pasteurellaceae virulence factor protein which:
a) is biologically inactive;
b) induces antibodies which specifically bind to virulence factor;
c) contains no foreign amino acid sequences;
d) contains an in-frame deletion; and
a pharmaceutically or veterinarily acceptable carrier.
